Augmerosen: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
No edit summary
Line 42: Line 42:
| molecular_weight =   
| molecular_weight =   
}}
}}
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Augmerosen''' is an [[antisense therapy|antisense]] [[oligonucleotide|oligodeoxyribonucleotide]] being studied as a possible treatment for several types of [[cancer]], including [[chronic lymphocytic leukemia]], [[B-cell lymphoma]], and [[breast cancer]]. It may kill cancer cells by blocking the production of [[Bcl-2]]—a [[protein]] that makes cancer cells live longer—and by making them more sensitive to chemotherapy.
==History==
An antisense [[oligonucleotide]] drug [[Genasense]] (G3139) has been developed by [[Genta (company)|Genta Incorporated]] to target Bcl-2. An [[antisense]] DNA or RNA strand is non-coding and complementary to the coding strand (which is the template for producing respectively RNA or protein). An [[antisense drugs|antisense drug]] is a short sequence of RNA which hybridises with and inactivates mRNA, preventing the protein from being formed.
It was shown that the proliferation of human [[lymphoma]] [[cell (biology)|cells]] (with t(14;18) translocation) could be inhibited by antisense RNA targeted at the start [[codon]] region of Bcl-2 [[mRNA]]. [[In vitro]] studies led to the identification of Genasense, which is complementary to the first 6 codons of Bcl-2 mRNA.<ref name="pmid12445555">{{cite journal | author = Dias N, Stein CA | title = Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides | journal = Eur J Pharm Biopharm | volume = 54 | issue = 3 | pages = 263–9 |date=November 2002 | pmid = 12445555 | doi = 10.1016/S0939-6411(02)00060-7| url = http://linkinghub.elsevier.com/retrieve/pii/S0939641102000607 }}</ref>
These have shown successful results in Phase I/II trials for lymphoma, and a large Phase III trial was launched in 2004.<ref name="pmid15010151">{{cite journal | author = Mavromatis BH, Cheson BD | title = Novel therapies for chronic lymphocytic leukemia | journal = Blood Rev. | volume = 18 | issue = 2 | pages = 137–48 |date=June 2004 | pmid = 15010151 | doi = 10.1016/S0268-960X(03)00039-0 | url =  }}</ref>
By the first quarter 2010, Genasense had not received [[Food and Drug Administration|FDA]] approval due to disappointing results in a melanoma trial. Although safety and efficacy of Genasense have not been established for any use, Genta Incorporated still claims on its website that studies are currently underway to examine the potential role of Genasense in a variety of clinical indications.
==References==
{{reflist|2}}
== External links ==
* [http://www.cancer.gov/dictionary?CdrID=44539 Augmerosen] entry in the public domain NCI Dictionary of Cancer Terms
{{Chemotherapeutic agents}}
[[Category:Drug]]

Revision as of 15:51, 10 April 2015

Augmerosen
Clinical data
ATC code
Identifiers
ChemSpider
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Augmerosen

Articles

Most recent articles on Augmerosen

Most cited articles on Augmerosen

Review articles on Augmerosen

Articles on Augmerosen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Augmerosen

Images of Augmerosen

Photos of Augmerosen

Podcasts & MP3s on Augmerosen

Videos on Augmerosen

Evidence Based Medicine

Cochrane Collaboration on Augmerosen

Bandolier on Augmerosen

TRIP on Augmerosen

Clinical Trials

Ongoing Trials on Augmerosen at Clinical Trials.gov

Trial results on Augmerosen

Clinical Trials on Augmerosen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Augmerosen

NICE Guidance on Augmerosen

NHS PRODIGY Guidance

FDA on Augmerosen

CDC on Augmerosen

Books

Books on Augmerosen

News

Augmerosen in the news

Be alerted to news on Augmerosen

News trends on Augmerosen

Commentary

Blogs on Augmerosen

Definitions

Definitions of Augmerosen

Patient Resources / Community

Patient resources on Augmerosen

Discussion groups on Augmerosen

Patient Handouts on Augmerosen

Directions to Hospitals Treating Augmerosen

Risk calculators and risk factors for Augmerosen

Healthcare Provider Resources

Symptoms of Augmerosen

Causes & Risk Factors for Augmerosen

Diagnostic studies for Augmerosen

Treatment of Augmerosen

Continuing Medical Education (CME)

CME Programs on Augmerosen

International

Augmerosen en Espanol

Augmerosen en Francais

Business

Augmerosen in the Marketplace

Patents on Augmerosen

Experimental / Informatics

List of terms related to Augmerosen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Augmerosen is an antisense oligodeoxyribonucleotide being studied as a possible treatment for several types of cancer, including chronic lymphocytic leukemia, B-cell lymphoma, and breast cancer. It may kill cancer cells by blocking the production of Bcl-2—a protein that makes cancer cells live longer—and by making them more sensitive to chemotherapy.

History

An antisense oligonucleotide drug Genasense (G3139) has been developed by Genta Incorporated to target Bcl-2. An antisense DNA or RNA strand is non-coding and complementary to the coding strand (which is the template for producing respectively RNA or protein). An antisense drug is a short sequence of RNA which hybridises with and inactivates mRNA, preventing the protein from being formed.

It was shown that the proliferation of human lymphoma cells (with t(14;18) translocation) could be inhibited by antisense RNA targeted at the start codon region of Bcl-2 mRNA. In vitro studies led to the identification of Genasense, which is complementary to the first 6 codons of Bcl-2 mRNA.[1]

These have shown successful results in Phase I/II trials for lymphoma, and a large Phase III trial was launched in 2004.[2]

By the first quarter 2010, Genasense had not received FDA approval due to disappointing results in a melanoma trial. Although safety and efficacy of Genasense have not been established for any use, Genta Incorporated still claims on its website that studies are currently underway to examine the potential role of Genasense in a variety of clinical indications.

References

  1. Dias N, Stein CA (November 2002). "Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides". Eur J Pharm Biopharm. 54 (3): 263–9. doi:10.1016/S0939-6411(02)00060-7. PMID 12445555.
  2. Mavromatis BH, Cheson BD (June 2004). "Novel therapies for chronic lymphocytic leukemia". Blood Rev. 18 (2): 137–48. doi:10.1016/S0268-960X(03)00039-0. PMID 15010151.

External links

  • Augmerosen entry in the public domain NCI Dictionary of Cancer Terms